Robin Foà, MD, Sapienza University of Rome, Rome, Italy, describes current barriers to indicating CAR-T cells for acute lymphoblastic leukemia (ALL). Whilst immunotherapies such as blinatumomab with tyrosine kinase inhibitors (TKIs) such as ponatinib have been successfully approved for frontline ALL, CAR-T research has mostly targeted heavily pretreated patients and it is therefore necessary to evaluate it in earlier lines of therapy and without subsequent transplant. Prof. Foà highlights additional costs associated with CAR-Ts. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.